Management of immunotherapy-related toxicities, version 1.2019

John A. Thompson, Bryan J. Schneider, Julie Brahmer, Stephanie Andrews, Philippe Armand, Shailender Bhatia, Lihua E. Budde, Luciano Costa, Marianne Davies, David Dunnington, Marc S. Ernstoff, Matthew Frigault, Brianna Hoffner, Christopher J. Hoimes, Mario Lacouture, Frederick Locke, Matthew Lunning, Nisha A. Mohindra, Jarushka Naidoo, Anthony J. OlszanskiOlalekan Oluwole, Sandip P. Patel, Sunil Reddy, Mabel Ryder, Bianca Santomasso, Scott Shofer, Jeffrey A. Sosman, Momen Wahidi, Yinghong Wang, Alyse Johnson-Chilla, Jillian L. Scavone

Research output: Contribution to journalArticle

62 Scopus citations

Abstract

The aim of the NCCN Guidelines for Management of Immunotherapy-Related Toxicities is to provide guidance on the management of immune-related adverse events resulting from cancer immunotherapy. The NCCN Management of Immunotherapy-Related Toxicities Panel is an interdisciplinary group of representatives from NCCN Member Institutions and ASCO, consisting of medical and hematologic oncologists with expertise in a wide array of disease sites, and experts from the fields of dermatology, gastroenterology, neurooncology, nephrology, emergency medicine, cardiology, oncology nursing, and patient advocacy. Several panel representatives are members of the Society for Immunotherapy of Cancer (SITC). The initial version of the NCCN Guidelines was designed in general alignment with recommendations published by ASCO and SITC. The content featured in this issue is an excerpt of the recommendations for managing toxicity related to immune checkpoint blockade and a review of existing evidence. For the full version of the NCCN Guidelines, including recommendations for managing toxicities related to chimeric antigen receptor T-cell therapy, visit NCCN.org.

Original languageEnglish (US)
Pages (from-to)255-289
Number of pages35
JournalJNCCN Journal of the National Comprehensive Cancer Network
Volume17
Issue number3
DOIs
StatePublished - Mar 2019

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'Management of immunotherapy-related toxicities, version 1.2019'. Together they form a unique fingerprint.

  • Cite this

    Thompson, J. A., Schneider, B. J., Brahmer, J., Andrews, S., Armand, P., Bhatia, S., Budde, L. E., Costa, L., Davies, M., Dunnington, D., Ernstoff, M. S., Frigault, M., Hoffner, B., Hoimes, C. J., Lacouture, M., Locke, F., Lunning, M., Mohindra, N. A., Naidoo, J., ... Scavone, J. L. (2019). Management of immunotherapy-related toxicities, version 1.2019. JNCCN Journal of the National Comprehensive Cancer Network, 17(3), 255-289. https://doi.org/10.6004/jnccn.2019.0013